Evaluation of etiological, laboratory, and anthropometric characteristics of patients treated with the diagnosis of precocious puberty

Abstract

Objective: This study aimed to determine the etiological distribution of patients treated for precocious puberty and to compare the results of gonadotropin-releasing hormone (GnRH) analog treatment with clinical and laboratory data during the administration and follow-up period. Material and Methods: The files of patients treated with a diagnosis of precocious puberty between October 2016 and July 2019 in the pediatric endocrinology outpatient clinic were retrospectively analyzed. Results: While 39 (88.6%) of our patients with precocious puberty were female, five (11.4%) were male. True precocious puberty (TPP) was found in 42 patients (95.5%) and combined precocious puberty (CPP) in two patients (4.5%). While 37 (88.1%) of TPP patients were diagnosed with idiopathic precocious puberty, an organic cause was found in five patients. Both of the patients treated for CPP had late-onset congenital adrenal hyperplasia. The mean estimated adult height (EAH) before the treatment was 151.88±6.77 cm in our patients between the ages of 6 and 8 who were started on GnRH analog treatment with a diagnosis of TPP, while the mean EAH after treatment was 155.16±7.82 cm (p<0.001). An increase in body mass index-standard deviation score was found in patients who received triptorelin acetate treatment, but no statistically significant difference was found. Conclusion: Precocious puberty is more common in girls, and idiopathic TPP constitutes the majority of cases. GnRH analog treatment may contribut